What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? - Experience from AVOREN

被引：2

作者：

Bracarda, S. ^{[1
]}

Bellmunt, J. ^{[2
]}

Negrier, S. N. ^{[3
]}

Melichar, B. ^{[4
]}

Ravaud, A. ^{[5
]}

Jethwa, S. ^{[6
]}

Sneller, V. ^{[6
]}

Escudier, B. ^{[7
]}

机构：

[1] Sec Oncol Urol Med Oncol, Perugia, Italy

[2] Hosp Mar, Barcelona, Spain

[3] Ctr Leon Berard, F-69373 Lyon, France

[4] Palack Univ, Sch Med, Teaching Hosp, Dept Oncol, Olomouc, Czech Republic

[5] CHU Bordeaux, Hop St Andre, Bordeaux, France

[6] F Hoffmann La Roche Ltd, PBMO, Basel, Switzerland

[7] Inst Gustave Roussy, Dept Med, Villejuif, France

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71459-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：431 / 431

页数：1